Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

2020

Genethon announces expanded collaboration with (...)

2020

Genethon, a French laboratory dedicated to the design and development of gene therapy products for rare diseases, and Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced an expansion of their collaboration to develop a gene therapy approach for Duchenne muscular dystrophy. Microdystrophin has demonstrated significant efficacy in pre-clinical testing*. The agreement between Sarepta and Genethon paves the way for a clinical trial to begin in 2020. (...)

  • Lire la suite
  • Articles similaires

Algentech Granted US Patent For A Key Genome (...)

2020

ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950)The technology claimed by the patent amplifies the effectiveness of gene editing in eukaryotic cells and can be applied in synergy with nucleases, including zinc finger nucleases, TALENs, Crispr-Cas9… Read more

  • Lire la suite
  • Articles similaires

Conclusive results of a gene therapy trial in (...)

2020

Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction. Six of the nine patients are free of treatments related to complications generated by the disease. These results have been published in Nature Medicine. Genethon who had conducted initial preclinical and (...)

  • Lire la suite
  • Articles similaires